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Since the early reports of neurofibrillary Tau pathology in brains of some Huntington’s
disease (HD) patients, mounting evidence of multiple alterations of Tau in HD brain
tissue has emerged in recent years. Such Tau alterations range from increased total
levels, imbalance of isoforms generated by alternative splicing (increased 4R-/3R-Tau
ratio) or by post-translational modifications such as hyperphosphorylation or truncation.
Besides, the detection in HD brains of a new Tau histopathological hallmark known as
Tau nuclear rods (TNRs) or Tau-positive nuclear indentations (TNIs) led to propose HD as
a secondary Tauopathy. After their discovery in HD brains, TNIs have also been reported
in hippocampal neurons of early Braak stage AD cases and in frontal and temporal
cortical neurons of FTD-MAPT cases due to the intronic IVS10+16 mutation in the Tau
gene (MAPT) which results in an increased 4R-/3R-Tau ratio similar to that observed
in HD. TNIs are likely pathogenic for contributing to the disturbed nucleocytoplasmic
transport observed in HD. A key question is whether correction of any of the mentioned
Tau alterations might have positive therapeutic implications for HD. The beneficial
effect of decreasing Tau expression in HD mouse models clearly implicates Tau in HD
pathogenesis. Such beneficial effect might be exerted by diminishing the excess total
levels of Tau or specifically by diminishing the excess 4R-Tau, as well as any of their
downstream effects. In any case, since gene silencing drugs are under development to
attenuate both Huntingtin (HTT) expression for HD and MAPT expression for FTD-MAPT,
it is conceivable that the combined therapy in HD patients might be more effective than
HTT silencing alone.
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INTRODUCTION
Huntington’s Disease Overview
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a
mutation in the gene that encodes for the protein Huntingtin (Htt). This mutation consists on an
abnormal expansion of a CAG triplet (>35) in exon 1 of the gene that encodes for a stretch of
polyglutamine (polyQ) in the N-terminal region of the protein (Gusella et al., 1993; MacDonald
et al., 1993) and, thus, HD belongs to the group of the polyglutamine diseases (Zoghbi and Orr,
2000). Clinically, HD patients suffer multiple symptoms that include motor (involuntary body
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movements, chorea, dystonia, and gait abnormalities), cognitive
(decreases in attention and mental flexibility) and psychiatric
and/or behavioral impairment (apathy, irritability, impulsivity,
depression and suicidal wishes) due to the affectation of different
parts of the brain (Vonsattel and DiFiglia, 1998; Sturrock and
Leavitt, 2010; Kim and Fung, 2014). Population without the
disease has between 6 and 35 CAG triplets in theHTT gene, while
individuals with expansions of 40 or more repeats develop HD.
Carriers of 36–39 CAG repeats have lower penetrance and later
onset of the disease (Andrew et al., 1993). There is a relationship
between the length of CAG repeat and the onset and severity of
the disease leading to a worse prognosis as the length increases
[Snell et al., 1993; Genetic Modifiers of Huntington’s Disease
(GeM-HD) Consortium, 2019].
As in other polyglutaminopathies, illness is mainly due to
a toxic gain of function of the expanded polyQ-containing
protein and also of the expanded CAG-containing mRNA
(Shieh and Bonini, 2011; Nalavade et al., 2013; Martí, 2016)
rather than to a loss of function of mutant Htt (mHtt).
Although the latter may also contribute to some of the
HD-specific symptoms (Zuccato and Cattaneo, 2014). The Htt
protein is expressed ubiquitously throughout the body with
high levels in the brain and testes (Schulte and Littleton,
2011). It interacts with different partners that are implicated in
cellular dynamics -like cytoskeleton, endocytosis, trafficking, and
adhesion-, metabolism, protein turnover, transcription and RNA
processing (Kaltenbach et al., 2007) and participates in vesicular
transport, synaptic transmission and autophagy, playing a role
in embryogenesis, signal transduction and cell adhesion (Schulte
and Littleton, 2011; Smith-Dijak et al., 2019). The absence of Htt
causes embryonic lethality while mice lacking one Htt allele do
not show phenotypical changes (Nasir et al., 1995).
Regarding neuropathology, HD is characterized by neuronal
death, primarily of medium-sized spiny neurons of the striatum
producing a progressive atrophy of the basal ganglia (Hedreen
and Folstein, 1995; Mitchell et al., 1999) but also in other
structures that are related to cognition such as the cortex and
hippocampus (Zheng and Diamond, 2012), which explains the
different symptoms that patients suffer. Nowadays, there is no
cure for HD and, normally, death takes place between 15 and
20 years after the onset of the symptoms.
Truncated N-terminal portions of mHtt can be generated
through proteolytic cleavage by caspases, calpains or
other endoproteases and this favors the agglomeration of
mHtt—driven by the self-aggregation of polyQ. This process
eventually leads to the formation of oligomers and globular
intermediates that can interfere with multiple intracellular
functions in the cytoplasm (such as organelle and mRNA
transport, protein turnover, or mitochondrial function among
others) and in the nucleus where gene expression can get altered
(Graham et al., 2006). Besides, N-terminal fragments of mHtt are
not only produced by proteolytic cleavage but also by aberrant
splicing (Bates et al., 2015). Recently, it has been observed in
a cohort of 56 HD patients a decrease in the levels of total Htt
levels (using EM48 and CH00146 antibodies) and an increase
in the levels of the N-terminal fragment without alteration in
Htt mRNA levels. This is accompanied by an increase in Htt
oligomers without changes in monomers according to Sarkosyl
based protein fractionation, suggesting that abnormal translation
and/or protein turnover is responsible for Htt misregulation in
HD (St-Amour et al., 2018).
The aggregation of mHtt produces an histopathological mark
in form of spherical inclusions that are detected in the nuclei
and cytoplasm of neurons in HD patients (DiFiglia et al., 1997)
but also in different transgenic animal models like mice (Davies
et al., 1997) or Drosophila (Warrick et al., 1998). Inclusions can
be detected using antibodies against Htt but also against other
epitopes like polyQ or ubiquitin (DiFiglia et al., 1997; Sapp et al.,
1997; Vonsattel et al., 2008). There is growing evidence that HD
inclusions, in addition to mHtt, can nucleate other proteins like
those that are characteristic of other neurodegenerative diseases,
like α-synuclein -found in Parkinson’s disease (Corrochano et al.,
2012; Herrera and Outeiro, 2012; Tomas-Zapico et al., 2012),
TDP-43 -found in amyotrophic lateral sclerosis- (Schwab et al.,
2008; Coudert et al., 2019), or Tau -found in Tauopathies such as
Alzheimer’s disease (Fernández-Nogales et al., 2014; Vuono et al.,
2015; St-Amour et al., 2018).
Tau Overview
Tau Gene and Isoforms Generated by Alternative
Splicing
Tau is a microtubule-associated protein (MAP) that was first
discovered in 1975 by Weingarten when it was co-purified along
with tubulin (Weingarten et al., 1975). In humans, this protein
is encoded by the gene MAPT that is located in the region
q21.31 on chromosome 17 and contains 16 exons (Neve et al.,
1986; Andreadis et al., 1992), while in mouse is located on
chromosome 11. The human MAPT gene has two haplotypes,
the more common H1 and the unusual H2 haplotype. The
latter results from a large—approximately 970 kb—chromosomal
inversion and a 238 bp deletion in intron 9 (Stefansson et al.,
2005; Caillet-Boudin et al., 2015).
The MAPT gene is expressed at its highest levels in neurons
in the central nervous system where it contributes to the
maintenance of neuronal polarity by promoting microtubule
assembly and stability.
Multiple Tau isoforms are generated by alternative splicing.
The exons that are alternatively spliced in adult CNS are exons
2, 3 and 10, and their combinatorial usage generates six Tau
isoforms in the adult human brain (Andreadis, 2005; Liu and
Gong, 2008). On one hand, alternative splicing of exons 2 and
3 generates Tau isoforms that differ by the absence or the
presence of an insert of 29 or 58 amino acids—corresponding to
exons 2 or 2 and 3—in the N-terminal region. Thus, exon 2 can
appear alone but exon 3 never appears independently of exon
2. This way the so-called 0N, 1N or 2N isoforms are generated
(Andreadis et al., 1995). On the other hand, the exclusion or
inclusion of exon 10—encoding a 31 amino acid sequence that
provides one of the four possible tubulin-binding repeats in the
C-terminal region of the protein—results in either 3R or 4R
isoforms (Goedert and Spillantini, 2011).
The N-terminal region binds to plasma membrane
components to regulate interactions while the C-terminal
part of the protein binds microtubules (Derisbourg et al., 2015).
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If we focus our attention in the C-terminal region, 4R-Tau
isoforms bind microtubules with higher affinity and are
more efficient at promoting microtubule assembly in vitro
compared to 3R-Tau isoforms that have less affinity for
microtubules (Lu and Kosik, 2001). More precisely, both
4R-Tau and 3R-Tau isoforms increase the growth rate of
microtubules, but 3R-Tau shows less efficacy in protecting
microtubules from disassembly than 4R-Tau isoforms (Panda
et al., 2003). During development, 0N3R isoform is the
most abundant making 3R-Tau to predominate over 4R-Tau
(Kosik et al., 1989). However, in healthy human adult brain,
3R-Tau and 4R-Tau are equally represented (Goedert et al.,
1989). In the case of the adult mouse brain, 4R-Tau isoforms
are predominant (Kosik et al., 1989; Takuma et al., 2003).
The microtubule-binding repeats also comprise the paired-
helical filament (PHF) core that is the primary structure
of aggregated Tau filaments (Wischik et al., 1988) and
dysregulation of the balance between 3R-Tau and 4R-Tau
isoforms has been shown to contribute to neurodegeneration
(Liu and Gong, 2008), as we are going to comment in
more detail.
Functions of Tau
In healthy neurons, Tau is almost exclusively located in the
axon (Wang and Mandelkow, 2016) where, as mentioned,
it is implicated in microtubule assembly and stabilization.
Microtubules are polar structures with a plus and a minus-end
and they are formed from α and β-tubulin heterodimers.
Tau binds both α and β-tubulin subunits and can promote
microtubule growth (Witman et al., 1976; Kadavath et al., 2015).
The assembly of microtubules consists of a phase of rapid
polymerization and a steady-state, where no assembly occurs.
Assembly occurs at the plus end while disassembly occurs at
the minus end, keeping the overall length of the microtubule
equal. Tau reduces the frequency of depolymerization by binding
along the outer surface. Microtubule dynamics in the nervous
system requires a high degree of stability. While the N-terminal
region of Tau could contribute to the formation of microtubule
bundles as it functions as a spacer in between them (Chen
et al., 1992), the C-terminal region binds to microtubules to
regulate their polymerization (Cleveland et al., 1977). In healthy
conditions, due to its ability to modify microtubule dynamics
(Trinczek et al., 1999; Dixit et al., 2008), Tau contributes to
regulate different cellular functions such as transport of mRNA
and proteins along the axons, as well as neurite extension.
Accordingly, when Tau is knocked down, neurite formation is
inhibited altering processes such as neuronal differentiation or
synaptic plasticity (Caceres and Kosik, 1990; Kempf et al., 1996;
Stamer et al., 2002; Spillantini and Goedert, 2013). Moreover,
Tau is present in small amounts in dendrites and even in the
nucleus where it can bind to DNA protecting it from damage
(Wei et al., 2008; Violet et al., 2014). DNA binding of Tau takes
place at both genic and intergenic regions (Benhelli-Mokrani
et al., 2018) and results in modulation of gene expression (Siano
et al., 2019). Interestingly, nuclear Tau has also been involved in
nucleolar transcription (Maina et al., 2018) and the decrease in
nuclear Tau (detected with Tau-100 antibody) that takes place
in AD CA1 and dentate gyrus neurons along disease progression
might be pathogenic by leading to decreased protein synthesis
(Hernández-Ortega et al., 2016). Finally, different mutations that
alter the proportion of Tau isoforms as well as post-translational
modifications can modify the affinity of Tau for microtubules.
The differential interaction of 4R-Tau and 3R-Tau with the
microtubules may have important implications for neuronal
diseases as the regulated expression of both isoforms is required
for the correct function of the neurons. Therefore, in summary,
both a loss of function of Tau and a toxic gain of function due to
aggregate formation can contribute to neurodegeneration.
Post-translational Modifications of Tau
Tau protein can be modified after translation by
phosphorylation, glycosylation, ubiquitination, acetylation
or truncation, among others (Martin et al., 2011). Regarding
phosphorylation of Tau, it can be phosphorylated in serine,
threonine and tyrosine residues with 85 potential sites of
phosphorylation, of which 45 have been validated (Wang
and Mandelkow, 2016). The sites of phosphorylation can be
divided depending on the kinases that can phosphorylate
them: proline-directed kinases -like glycogen synthase kinase 3
(GSK-3), cyclin-dependent kinase 5 (CDK-5), cyclin-dependent
kinase 1 (CDK-1), mitogen-activated protein kinase (p38), c-Jun
N-terminal kinases (JNK), and other stress kinases—and non-
proline-directed kinases—like protein kinase A (PKA), protein
kinase C (PKC), calmodulin kinase II (CaMK-II), microtubule
affinity regulating kinase (MARK) or casein kinase 2 (CK2).
Phosphorylation of Tau reduces its affinity for microtubule
and different plasma membrane components, thus reducing
microtubule stability. For example, phosphorylation on Ser-214
and Thr-231 promotes detaching of Tau from microtubules.
Deregulation of Tau phosphorylation is deleterious for neurons
and has been implicated in many diseases such as AD,
where Tau hyperphosphorylation favors its detachment from
the microtubules thus increasing the levels of soluble Tau
available for self-aggregation leading to the formation of
neurofibrillary tangles (NFT) and/or neuropil threads (NT;
Wang and Mandelkow, 2016). GSK-3 is believed to play an
important role in Tau hyperphosphorylation as it is able
to phosphorylate the majority of the residues which are
hyperphosphorylated in AD (Lovestone et al., 1994) and its levels
are increased in AD brains (Pei et al., 1997). Apart from kinase
hyperactivity, dysregulation of phosphatases can also lead to
pathogenic hyperphosphorylation. Different phosphatases such
as PP1, PP2A, PP2B (calcineurin) and PP2C can eliminate
phosphates from Tau but only PP1, PP2A, and PP2B (Gong
et al., 2004) have been shown to dephosphorylate abnormally
hyperphosphorylated Tau.
Not only phosphorylationmodulates Tau activity. Acetylation
can also regulate its function as it has been observed that, in vitro,
it can preclude microtubule assembly (Min et al., 2010; Cohen
et al., 2011). Important sites of acetylation are K163, K274, K280,
K281, and K369, with K281 and K274 being acetylated in AD
patients (Tracy et al., 2016). Interestingly, when the levels of
acetylated Tau are increased, its levels of phosphorylation are
reduced (Min et al., 2010).
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Other post-translational modifications that include
N-glycosylation, truncation and isomerization stabilize
PHFs. It has been described that N-glycosylation is related
to Tau hyperphosphorylation and Tau aggregation (Ledesma
et al., 1995). N-glycosylation stabilizes aggregated PHFs
leading to tangle formation in AD. Phosphorylation on
Ser-717 completely abolishes the O-GlcNAcylation on this
site, while phosphorylation on Ser-713 and Ser-721 reduces
O-GlcNAcylation. O-GlcNAcylation on Ser-717 decreases the
phosphorylation on Ser-721 by about 41.5%. Truncation of Tau
can also promote aggregation as Tau fragments have been found
in the PHFs of AD patients (Wischik et al., 1988).
Finally, Tau can be ubiquitinated and this modification
has mainly been found in aberrant aggregates such as the
inclusion bodies found in Pick’s or Parkinson’s diseases or
in PHFs in AD (Mayer et al., 1989; Morishima-Kawashima
et al., 1993). PHF-Tau can be modified by three different forms
of poly-ubiquitination, ‘‘Lys-48’’-linked poly-ubiquitination
is the major form but ‘‘Lys-6’’-linked and ‘‘Lys-11’’-linked
poly-ubiquitination could also occur.
Tau Mutations and Tauopathies
The alteration of the amount and the structure of the Tau
protein can disturb its localization and, as a consequence, its
function producing different pathological effects. Tauopathies
are a class of neurodegenerative disorders that are characterized
by the aggregation and intracellular deposition of Tau in neurons
and/or glial cells as a consequence of abnormal increase in the
levels of phosphorylation, abnormal splicing of the mRNA or
mutations inMAPT gene.
Tauopathies can be divided into: (a) primary Tauopathies
that are a major class of Frontotemporal Lobar Degeneration
(FTLD) neuropathology and can present clinically with
several forms of Frontotemporal Dementia (FTD)—like
Frontotemporal Dementia with parkinsonism linked to
chromosome 17—(FTDP-17), progressive supranuclear palsy
syndrome (PSP) or corticobasal degeneration (CBD); and
(b) secondary or non-primary Tauopathies like Alzheimer’s
disease (AD) in which neurofibrillary Tau neuropathology
occurs in addition to the amyloid-β (Aβ) plaques. The various
Tauopathies affect different brain regions and cell types and they
also show differences in the ratio of Tau isoforms present in the
Tau filaments (Sergeant et al., 2005). In AD, there are similar
levels of 3R-Tau and 4R-Tau in the PHFs (Goedert et al., 1995)
while other Tauopathies like PSP or CBC show an increase in
4R-Tau isoforms and others like PiD show an increase in 3R-Tau
isoforms (Arendt et al., 2016).
Missense, silent and intronic mutations in the MAPT gene
have been directly related to different Tauopathies or constitute
a risk factor for them (Goedert and Jakes, 2005). In 1998,
it was discovered that mutations on the MAPT gene cause
FTDP-17, confirming that Tau dysfunction is sufficient to
cause neurodegeneration. These patients showed filamentous
Tau inclusions in neurons and glia and atrophy of the frontal
and temporal lobes (Hutton et al., 1998; Poorkaj et al., 1998;
Spillantini et al., 1998). There are different missense mutations
like ∆K280, P301L, G272V, V337M, R406W and N279K that
reduce microtubule assembly contributing to PHFs stabilization
and its aggregation forming NFTs (Barghorn et al., 2000).
Regarding intronic mutations, they are located around exon
10 affecting its rate of inclusion and they lead to an imbalance
of the ratio of 4R- and 3R-Tau isoforms (Liu and Gong, 2008).
TAU PATHOLOGY IN HUNTINGTON’S
DISEASE
Along the last decades, many studies have demonstrated Tau
alterations and Tau-positive histopathological hallmarks in HD
patients as well as in animal models that could be contributing
to the progression of the disease. Here, we aim to review these
pieces of evidence to elucidate the role of Tau in the disease and
to elaborate on whether this offers opportunities for therapeutic
interventions to ameliorate HD prognosis.
Polymorphisms
It has been described that the MAPT H1 haplotype—that is
the most abundant—could be a genetic risk factor for some
Tauopathies like PSP or CBD (Houlden et al., 2001; Pittman
et al., 2004). Also, H1 haplotype increases the expression of total
MAPT transcript as well as specifically increases the inclusion
of exon 10 and therefore the proportion of 4R-Tau isoforms
(Myers et al., 2007). In HD, Tau polymorphisms have been linked
to the progression of cognitive deficits. In a group of 960 HD
patients that were genotyped for the H1 and H2 haplotypes-
using the SNP rs9468, Vuono et al. (2015) reported that there
is a correlation between increased number of CAG repeats and
increased rate of cognitive decline in H2 carriers and that Tau
H2 haplotype carriers show accelerated cognitive deterioration
compared to H1/H1 homozygous carriers.
Tau Levels
Regarding Tau protein levels, a high increase in the levels of total
Tau (Tau-5 antibody) was found in the cortex of HD patients
and this is accompanied with the appearance of lower molecular
weight (35 and 39 KD) bands (Fernández-Nogales et al., 2014),
while no changes were found in the striatum (Fernández-Nogales
et al., 2014). However, a more recent report has shown elevated
Tau total mRNA levels in the putamen of HD patients (St-Amour
et al., 2018). Importantly, the presence of an excess of Tau in HD
brains most likely contributes to disease as Tau knock-down has
been demonstrated to attenuate motor abnormalities in an HD
mouse model (Fernández-Nogales et al., 2014).
Aberrant Splicing of Tau in HD
As previously commented, in some Tauopathies including PSP,
CB, Pick’s disease (PiD) and FTLD with Tau+ inclusions (FTLD-
Tau), alteration of alternative splicing of exon 10 produces
an imbalance in 4R-Tau and 3R-Tau isoforms (Park et al.,
2016). Regarding HD, we demonstrated that patients (andmouse
models of the disease, like the R6/1 and HD94 mice) show an
increase in the ratio 4R-Tau/3R-Tau mRNA isoforms in cortex
and striatum, accompanied by an increase of the levels of 4R-Tau
protein. In the striatum, there also was a decrease in 3R-Tau
protein (Fernández-Nogales et al., 2014). The imbalance of 4R-
Tau/3R-Tau mRNA isoforms was corroborated by Vuono et al.
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(2015) in the cortex and striatum of a cohort of 16 patients.
More precisely, they detect 1N3R and 2N4R mRNA and protein
isoforms and found an increase in 4R-Tau isoforms that leads
to an altered ratio of isoforms. Recently, using putamen samples
from a higher number of patients (St-Amour et al., 2018), it
was shown a 2.5-fold increase in 4R-Tau/3R-Tau ratio at the
protein level and a 1.8-fold increase at the mRNA level, due
to an upregulation of 4R-Tau isoforms. The high number of
samples analyzed in that study allowed them to conclude that
the top increment takes place in grade 2 cases regarding the
mRNA and in grade 3 cases regarding the protein, resulting in
higher 0N4R and lower 1N3R isoforms (St-Amour et al., 2018).
All these findings regarding altered isoform ratio in HD are very
relevant in view of the fact that alteration in the ratio of 4R-Tau
and 3R-Tau isoforms is sufficient to cause neurodegeneration
(Hutton et al., 1998; Qian and Liu, 2014), as this might
contribute per se to HD neurodegeneration independently of
other deleterious effects of mHtt, thus becoming a therapeutic
target for HD.
Alternative splicing of exon 10 is regulated by a system
of factors that bind to the RNA regulating the splicing of
the pre-mRNA itself. Among these factors, the family of
the serine- and arginine-rich (SR) proteins participate on
constitutive splicing while also regulating alternative splicing.
Some members of this family promote the inclusion of exon 10,
while others suppress it. Several studies have shown that SRSF1
(ASF/SF2), SRSF2 (SC35), SRSR6 (SRp55), and SRSF9 (SRp30c)
promote exon 10 inclusion, while SRSF3, SRSF4, SRSF7, and
SRSF11 suppress its inclusion (Qian and Liu, 2014).
It was bioinformatically predicted (Sathasivam et al., 2013)
and biochemically confirmed (Schilling et al., 2019) that the
splicing factor SRSF6 can bind CAG RNA repeats and this
leads to incomplete splicing of Htt RNA and to production
of a small form of Htt known as exon 1-Htt (Sathasivam
et al., 2013). Besides, SRSF6 was indeed found altered in the
striatum of HD patients and in the R6/1 mouse model of the
disease, as it gets sequestered into mHtt inclusions (Fernández-
Nogales et al., 2014). The activity and localization of SR
proteins could be modulated by post-translational modifications
such as phosphorylation of their multiple serine and threonine
residues, and such phosphorylation is required, in general, for the
translocation of SR proteins from the cytoplasm to the nucleus.
In this regard, it has been shown an increase in the levels of
phosphorylation of SRSF6 in the striatum and cortex of HD
patients and R6/1 mice (Fernández-Nogales et al., 2014) which
may favor dissociation from nuclear speckles (Yin et al., 2012;
Naro and Sette, 2013). This, together with the sequestration of
SRSF6 intomHtt inclusions, suggests a decrease in SRSF6 activity
that could explain themodulation observed of exon 10 splicing in
HD. Moreover, SRSF6 not only modulates alternative splicing of
MAPT, as it alsomodulates alternative splicing ofMAP2, another
MAP whose alternative splicing is altered in HD (Cabrera and
Lucas, 2017).
Recently, it has been proposed the splicing factor proline- and
glutamine-rich (SFPQ) could also be responsible for the
4R-Tau/3R-Tau imbalance as it has been shown to modulate
exon 10 splicing and to interact with FUS, one major component
of mHtt inclusions (Fujioka et al., 2013; Ishigaki et al., 2017).
Although no association was apparent between SFPQ nuclear
signal intensity and presence or absence of HD-associated
intranuclear inclusions in striatal and cortical neurons of seven
HD cases (Baskota et al., 2019), the reduced nuclear availability
of free FUS in HD and, as a consequence, a decreased interaction
with SFPQ, might affect 4R-Tau/3R-Tau ratio.
More recently, St-Amour et al. (2018) have explored the
alternative splicing that affects exon 2 and 3 on the MAPT
gene. It has been observed an increase of 1.7 fold-change in
the isoforms that do not contain exons 2 and 3 (0N-Tau) at
mRNA level and a 0.5 fold-change in the isoforms that only
contain exon 2 (St-Amour et al., 2018). Further investigation
is required to know the effect of the alteration in the ratio of
these isoforms in the progression of the disease as the N-terminal
region of Tau participates in the interaction with different
membrane components.
Tau Phosphorylation in HD
As previously described, Tau functions are modulated by
site-specific phosphorylation and its alteration produce a toxic
loss of function as the microtubule-binding ability is decreased,
but also a toxic gain of function as it generates deposits as a
result of its aggregation. There are multiple studies showing
Tau hyperphosphorylation in HD that could contribute to
the disease. The first evidence of Tau hyperphosphorylation
in HD patients was obtained by immunohistochemistry with
the AT8 antibody which revealed positive staining -with or
without NTs in 13 of 27 analyzed patients (Jellinger, 1998).
In good agreement, a recent study on 16 cases including
young HD cases (26 and 40 years) has shown AT-8 positive
neuronal inclusions with different shapes and conformations like
ring-like perinuclear, flame-shaped and globular inclusions in
the cortex and striatum as well as astrocytic plaques, NT, dots
and nuclear rods (Gratuze et al., 2015; Vuono et al., 2015). Using
antibodies other than AT-8, an increase in Tau phosphorylation
at Ser396/Ser404/Ser199 and Thr205 epitopes, while no changes
in epitopes Ser235/Ser262/Ser356, has been observed in the
putamen of a cohort of 56 patients (St-Amour et al., 2018).
Recently, hyperphosphorylated Tau (detected with antibodies
AT8, CP13, AT180b and PHF-1) has been detected in fetal tissue
transplanted into cortex and striatum of two HD cases (Cisbani
et al., 2017).
There is some controversy regarding the presence of
hyperphosphorylated Tau in the Sarkosyl-insoluble fraction
obtained from HD brains. While Vuono et al. (2015) found
elevated AT-8 Tau in this fraction, two different studies
failed to replicate this. More precisely, we did not detect
hyperphosphorylated Tau (with AT-8 or with PHF-1) in this
insoluble fraction of HD brains (Fernández-Nogales et al., 2014)
and neither did the more recent study by St-Amour et al.
(2018) which analyzed a much higher number of HD cases.
Interestingly, in the latter, they report that multiple antibodies
against Tau phospho-epitopes were below detection levels in the
Sarkosyl-insoluble fraction.
Regarding cellular and animal models of HD, mHtt
expression promotes Tau hyperphosphorylation at Ser396 as
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evidenced in cells in which Tau was co-transfected with mHtt,
in contrast to what happens when Tau is co-transfected with
wild type Htt in which the levels of phosphorylation are
maintained stable (Blum et al., 2015). The Q111 striatal knock-in
cellular model that mimics the polyglutamine expansion shows
Tau hyperphosphorylation when there is pharmacological
inhibition of PP2B/calcineurin in comparison with Q7 cells
(Gratuze et al., 2015).
In animal models of HD, there are plenty of demonstrations
of Tau hyperphosphorylation. Thus, Gratuze et al. (2015)
showed increased Tau hyperphosphorylation at PHF-1 epitope in
presymptomatic R6/2 whereas symptomatic R6/2 mice displayed
Tau hyperphosphorylation at multiple Tau phospho-epitopes
like AT-8, CP13, PT205 and PHF1 in the hippocampus. Besides,
the zQ175 knock-in mice show increased phosphorylation with
PS199. Similarly, Blum et al. (2015) showed that R6/2 and
KI140 mice display increased phosphorylation in Ser404 and
Ser396 by western blot and also by immunofluorescence with
the pSer396 antibody in KI140 mice. Besides, they also detected
a decrease in Tau1 (unphosphorylated Tau) in R6/2 and
KI140 mice.
The phosphorylation of Tau is a balance between the activity
of its kinases and phosphatases (Sergeant et al., 2008). One of
the main kinases that phosphorylates Tau is GSK-3 which has
been shown to mediate Tau phosphorylation in Alzheimer’s
disease (Hernandez et al., 2013) and bipolar disorder (Beaulieu
et al., 2004; Li et al., 2010). However, there is a dramatic
decrease in GSK-3 levels and activity in the striatum and
cortex from HD patients (Lim et al., 2014; Fernández-Nogales
et al., 2015) as well as in R6/1 mouse model (Saavedra et al.,
2010; Fernández-Nogales et al., 2015), while an increase in
active pGSK-3β-Tyr216 does take place in hippocampus of HD
patients and R6/2 mice (L’Episcopo et al., 2016). It has been
reported that GSK-3β, CamKII, AKT, JNK, p38, ERk or CDK-5
are not activated in R6/2 and Q175 mice and there is even
increased Ser9 phosphorylation of GSK-3β (resulting in the
inactive form of the kinase) and reduced phosphorylation and
levels of CamKII, as well as reduced cdk5 and ERK expression
in the cortex of R6/2 and KI140 mice (Deckel et al., 2002;
Blum et al., 2015; Gratuze et al., 2015). Together, all these
results do not fit with the Tau hyperphosphorylation observed
in HD. In contrast, and regarding the phosphatases implicated
in Tau dephosphorylation, it has been shown a decrease in
PP1, PP2A and PP2B expression in R6/2 mouse model and a
significant reduction in Calcineurin/PP2B expression in KI140
(Blum et al., 2015; Gratuze et al., 2015) which may explain the
hyperphosphorylation phenotype.
Tau Truncation in HD
As mentioned, Tau truncation may be relevant to
neurodegeneration as it may alter the Tau function and
favor the formation of Tau aggregates. There are different
truncated forms of Tau depending on the protease responsible
for the cleavage. The ∆Tau314 has been demonstrated to be
generated by Casp2 and to cause synaptic dysfunction and
cognitive deficits in cellular and transgenic mouse models of
FTDP-17 (Zhang et al., 2014). Recently, it has been reported
that both Casp2 and ∆Tau314 proteins are higher in the
striatum (caudate nucleus) and prefrontal cortex (Brodmann’s
area 8/9) of HD patients as compared non-HD individuals
(Liu et al., 2019).
TAU-POSITIVE NUCLEAR MEMBRANE
INVAGINATIONS AND OTHER
HISTOPATHOLOGICAL MARKS IN HD
For decades, there have been numerous histopathological
reports of HD patients in whom the presence of NFT—the
histopathological hallmark characteristic of different
Tauopathies such as Alzheimer’s disease—has been detected
(McIntosh et al., 1978; Myers et al., 1985; Reyes and Gibbons,
1985; Moss et al., 1988; Caparros-Lefebvre et al., 2009). More
systematic studies using larger patient cohorts have detected
Tau pathology in 60% (16/27; Jellinger, 1998) or 80% (9/11;
Davis et al., 2014) of HD cases. Due to the growing evidence
of the presence of Tau pathology in HD patients and in an
attempt to understand how it may or may not contribute to
the pathology of the disease, different studies in which animal
models and patients are used have tried to systematically analyze
this question.
mHtt and Tau Co-localization
Different approaches have been attempted to study if mHtt
and Tau are directly or indirectly related to understand
the mechanism of the confluence of both proteinopathies in
HD patients. Some co-localization between mHtt aggregates
(evidenced with EM48 antibody) and Tau deposits stained with
antibodies that recognize 3R-Tau, 4R-Tau or pathologically
phosphorylated Tau (AT-8 and pS199) has been detected in
cortical and striatal sections of HD patients (Vuono et al.,
2015). In contrast, other studies have failed to detect Tau
within HD inclusions. For instance, Tau (Ht-7 antibody) could
not be found in mHtt inclusions (evidenced with ubiquitin
antibody) by immunofluorescence in cortical tissue of HD
patients (Fernández-Nogales et al., 2014). Similarly, in animal
models, no co-localization of both proteins could be found
by confocal immunofluorescence using Tau pSer396 and mHtt
(2B4 or EM48) antibodies in KI140 mice (Blum et al., 2015).
To clarify if there is or not an authentic co-localization
between both proteins, different co-immunoprecipitation
studies have been performed. In human tissue, no
co-immunoprecipitation between both proteins was observed
using the Tau 5 antibody that detects total Tau and the EM-48 in
striatal homogenates of HD patients (Fernández-Nogales et al.,
2014). No co-immunoprecipitation between both proteins was
achieved either with cortical samples of KI140 mice nor was Tau
detected in cortical Sarkosyl-insoluble protein fractions from
R6/2 mice (Blum et al., 2015). Interestingly, in BIFC experiments
in vitro with constructs with 25Q (wt) or 103Q mHtt and Tau
fused with non-fluorescence halves of a fluorescence reporter
protein, Blum et al. (2015) observed that when they put together
103Q and Tau, 103QHtt is recruited in the microtubular
cytoskeleton network. Besides, Tau is hyperphosphorylated and,
although its subcellular distribution is altered and its aggregation
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FIGURE 1 | Presence of Tau nuclear indentations (TNIs) in Huntington’s disease (HD) brains. (A) Immunoelectron microscopy analysis of HD neurons with HT-7
positive nuclear indentations. Red arrows indicate the diaminobenzidine precipitate. (B) Immunohistochemistry with RD4 and Ht-7 antibodies in neurons of HD brain.
(C) HT-7 immunofluorescence (green) with DAPI (blue) counterstaining in HD striatal neurons.
favored, it is not obvious the existence of a toxic interaction of
both proteins and further studies are needed to clarify that.
Tau-Positive Cytoplasmic Aggregates
In view of the abnormal Tau ‘‘processing’’ that we initially
detected in HD brains (Fernández-Nogales et al., 2014) that
leads to an alteration of 4R-Tau/3R-Tau ratio in favor
of 4R-Tau isoforms (similar to that seen in some FTD
forms caused by intronic Tau mutations), we explored the
possibility of Tau deposits in HD brains. We detected granular
cytoplasmic Tau deposits which often form perinuclear rings
in cortical and striatal neurons (Fernández-Nogales et al.,
2014) by immunohistochemistry with antibodies that recognize
4R-Tau isoforms (RD4), 3R-Tau isoforms (RD-3) or Total Tau
(Tau-5 and HT-7), but not with anti-phospho-Tau antibodies.
Vuono et al. (2015) detected similar Tau deposits like perinuclear
rings, flame-shaped and globular inclusions as well as astrocytic
plaques in striatum and cortex of HD subjects but, in this case,
with an antibody against phosphorylated Tau (AT-8). Similarly,
in a more recent study, Cisbani et al. (2017) also detected AT-8
positive neuronal inclusions—apart from NFTs and NTs—in
striatum and cortex of HD patients.
Tau-Positive Nuclear Membrane
Invaginations
Interestingly, we also described for the first time the presence
of Tau nuclear indentations (TNIs) also known as Tau Nuclear
Rods (TNRs) in the striatum and cortex of HD patients
(Fernández-Nogales et al., 2014). We detected TNIs using
antibodies that recognize 4R-Tau isoforms (RD4), 3R-Tau
isoforms (RD-3), Total Tau (Tau-5 and HT-7) or Tau oligomers
(T22), but not with antibodies against phosphorylated Tau
(such as AT-8 or PHF-1; Fernández-Nogales et al., 2014).
Immuno-electron microscopy with HT-7 antibody revealed
that this structure has an ordered filamentous ultrastructure
immunopositive for Tau that fills neuronal invaginations of
the nuclear envelope that partially or totally span the neuronal
nuclear space (Fernández-Nogales et al., 2014). This new Tau
histopathological hallmark thus seems to fill the previously
reported neuronal nuclear membrane invaginations detected in
ultrastructural analyses and whose incidence is higher in striatum
of HD patients than in control subjects (Bots and Bruyn, 1981;
Roos and Bots, 1983). Examples of TNIs evidenced by IHC, IF
and immuno-EM are shown in Figure 1. The presence of TNIs in
HD brains was confirmed in an independent study with a higher
number of HD patient samples (Vuono et al., 2015) although,
in this case, using the AT-8 antibody against phosphorylated
Tau. In contrast, a recent study on samples from seven HD cases
(Vonsattel grades 3 and 4), failed to detect TNIs (Baskota et al.,
2019) and they reasoned that this may be due to technical features
because the variety of antibodies they used did not detect neurons
with cytoplasmic Tau staining, which are the ones displaying
TNIs in the above-mentioned studies which do detect them. In
HD mouse models, TNIs have also has been detected with Tau-5
and RD4 antibodies in the R6/1 and HD94 mice although with
much lower abundance than in human HD tissue (Fernández-
Nogales et al., 2014).
Interestingly, TNIs can be found in brain tissue of other
neurodegenerative diseases. More precisely, in two Tauopathies:
AD and FTD. Thus, we detected TNIs in the hippocampus
of different Braak stage AD patients using the RD4 antibody
(Fernández-Nogales et al., 2014). More recently, TNIs have also
been detected in frontal and temporal cortex samples from two
independent cohorts of patients with FTD-MAPT due to the
MAPT intronic IVS10+16 mutation (Paonessa et al., 2019). Such
mutation increases exon 10 inclusion and, therefore, increases
the 4R-Tau/3R-Tau ratio in favor of 4R-Tau isoforms (similar to
what we have described in HD brains).
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Paonessa et al. (2019) also detected increased incidence of
TNIs in IPSC-neurons derived from FTD-MAPT cases due to the
MAPT IVS10+16 mutation and also, but to a lower extent, from
FTD-MAPT cases due tomissense P301Lmutation that produces
an aggregation-prone form of Tau.
Regarding the possible pathogenic relevance of TNIs, lamin
dysfunction and neuronal nuclear indentations in AD have
been linked to the improper cytoskeletal/nucleoskeletal coupling
that was suggested as a novel mediator of neurotoxicity in
Tauopathies (Frost et al., 2016) and more recently, pathological
Tau has been shown to impair nucleocytoplasmic transport in
Tau-overexpressing mice and AD brain tissue (Eftekharzadeh
et al., 2018) which has been further confirmed recently
(Paonessa et al., 2019). In this regard, nuclear integrity
and nucleocytoplasmic transport have also been reported
altered in Huntington‘s disease (Gasset-Rosa et al., 2017;
Grima et al., 2017).
Regarding the mechanism by which TNIs get formed, analysis
of a transgenic mouse model that overexpresses human 4R-Tau
with a FTLD with the P301S Tau point mutation revealed
that Tau alteration is sufficient for TNI formation/detection
(Fernández-Nogales et al., 2017). Similarly, a Drosophila model
with pan-neuronal expression of a disease-causing mutant form
of human Tau, TauR406W, produces nuclear invagination that
co-localizes with phosphorylated Tau (Cornelison et al., 2019).
These observations raised the question of whether increased Tau
(either total Tau or 4R-Tau regardless of point mutations) fills
nuclear invaginations formed by Tau-independent mechanisms
or whether the incidence of nuclear envelope invaginations
increases upon Tau alteration, for instance, because it stabilizes
microtubule bundles that deform the nucleus. The latter is
precisely what Paonessa et al. (2019) demonstrate in human
iPSC-derived neurons with MAPT P301L and MAPT IVS16+
10 mutations as treatment with nocodazole significantly reduced
the proportion of neurons with nuclear invaginations and
restored round nuclear morphology. This is in contrast with the
fact that the number of nuclear indentations in hippocampal
neurons of P301S mice is not higher than in wild type mice
(Fernández-Nogales et al., 2017). In case the induction of nuclear
envelope invagination upon Tau alteration occurred only in
culture, TNI detection in histopathological analysis still emerges
as an efficient way to screen for brains with altered Tau (levels,
isoform ratio, or simply function). Additional work will be
needed to clarify this.
PATHOGENIC AND THERAPEUTIC
IMPLICATIONS: FUTURE DIRECTIONS
Here we have shown multiple alterations of Tau in HD brain
tissue which range from increased total levels, imbalance of
alternative splicing-generated isoforms, hyperphosphorylation
and truncation, to the formation of Tau-positive cytoplasmic
aggregates and nuclear envelope invaginations. The likely
pathogenic role of the latter—through interference of nuclear
envelope function—and the possible mechanisms by which
TNIs are formed are also discussed. A key question is whether
correction of any of these tau alterations and of this Tau
histopathological hallmark might have positive therapeutic
implications for the disease.
Regarding the therapeutic implications of the current
knowledge of the involvement of Tau in HD pathogenesis, a
convincing evidence supporting that Tau contributes to HD
pathogenesis originates from the beneficial effect of decreasing
Tau expression in HD mouse models by combining with
Tau knock-out mice—even partial reduction in heterozygous
knock-out background (Fernández-Nogales et al., 2014). This
beneficial effect might be due to the attenuation of the excess
total levels of Tau in the cortex of HD mice or by attenuation
specifically of the excess 4R-Tau observed both in striatum and
cortex. But in any case, since gene silencing drugs are under
development to attenuate both HTT expression for HD and to
attenuate MAPT expression for FTD-MAPT (Mullard, 2019), it
is conceivable that the combined therapy in HD patients might
be more effective than HTT silencing alone.
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